CO2023001340A2 - Formulaciones a largo plazo - Google Patents

Formulaciones a largo plazo

Info

Publication number
CO2023001340A2
CO2023001340A2 CONC2023/0001340A CO2023001340A CO2023001340A2 CO 2023001340 A2 CO2023001340 A2 CO 2023001340A2 CO 2023001340 A CO2023001340 A CO 2023001340A CO 2023001340 A2 CO2023001340 A2 CO 2023001340A2
Authority
CO
Colombia
Prior art keywords
long term
pharmaceutical compositions
term formulations
formulations
bedaquiline
Prior art date
Application number
CONC2023/0001340A
Other languages
English (en)
Inventor
René Holm
Iwan Caroline F Vervoort
Wenyu Dong
Miriam Colombo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2023001340A2 publication Critical patent/CO2023001340A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Esta invención se refiere a composiciones farmacéuticas para la administración por vía intramuscular o inyección subcutánea, que comprende micro o nanopartículas del compuesto bedaquilina anti-TB, suspendido en un vehículo acuoso farmacéuticamente aceptable, y que comprende PEG4000 como un modificador de superficie, y al uso de tales composiciones farmacéuticas en el tratamiento y profilaxis de una infección por micobacterias patógenas.
CONC2023/0001340A 2020-07-09 2023-02-08 Formulaciones a largo plazo CO2023001340A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20185105 2020-07-09
PCT/EP2021/068956 WO2022008643A1 (en) 2020-07-09 2021-07-08 Long-acting formulations

Publications (1)

Publication Number Publication Date
CO2023001340A2 true CO2023001340A2 (es) 2023-02-27

Family

ID=71575093

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001340A CO2023001340A2 (es) 2020-07-09 2023-02-08 Formulaciones a largo plazo

Country Status (12)

Country Link
US (1) US20230241051A1 (es)
EP (1) EP4178546A1 (es)
JP (1) JP2023533014A (es)
KR (1) KR20230038521A (es)
CN (1) CN115867259A (es)
AU (1) AU2021303490A1 (es)
BR (1) BR112023000220A2 (es)
CA (1) CA3182425A1 (es)
CO (1) CO2023001340A2 (es)
MX (1) MX2023000439A (es)
PE (1) PE20231296A1 (es)
WO (1) WO2022008643A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183276A1 (en) * 2022-03-22 2023-09-28 University Of Southern California Adjunctive treatment of mycobacterial diseases
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
PL222801B1 (pl) 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je
JP2007501683A (ja) 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
JP5410749B2 (ja) 2005-05-25 2014-02-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールの製造方法
UA97641C2 (en) 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Aqueous suspensions of tmc278
US9421194B2 (en) * 2010-04-05 2016-08-23 Rutgers, The State University Of New Jersey Lung targeting dual drug delivery system
SI2696848T1 (sl) 2011-04-15 2020-10-30 Janssen Pharmaceutica N.V. Liofilizirane zdravilne nanosuspenzije
WO2019012100A1 (en) 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS

Also Published As

Publication number Publication date
AU2021303490A1 (en) 2023-03-09
US20230241051A1 (en) 2023-08-03
EP4178546A1 (en) 2023-05-17
BR112023000220A2 (pt) 2023-01-31
CN115867259A (zh) 2023-03-28
CA3182425A1 (en) 2022-01-13
WO2022008643A1 (en) 2022-01-13
PE20231296A1 (es) 2023-08-22
KR20230038521A (ko) 2023-03-20
MX2023000439A (es) 2023-02-09
JP2023533014A (ja) 2023-08-01

Similar Documents

Publication Publication Date Title
CO2023001340A2 (es) Formulaciones a largo plazo
CO2020000328A2 (es) Formulaciones a largo plazo
ECSP22018209A (es) Nanopart?culas lip?dicas mejoradas para el suministro de ?cidos nucleicos
AR061620A1 (es) Suspensiones acuosas de tmc278
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CL2008002228A1 (es) Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas.
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
CO2019001044A2 (es) Composición de cannabis
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CR20180388A (es) Formulaciones para el tratamiento del cáncer de vejiga
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CO6640318A2 (es) Formas de dosificación oral de bendamustina
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
UY38982A (es) Composiciones farmacéuticas
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
BR112017016429A2 (pt) ?vacina, uso de um antígeno de lawsonia intracellularis não vivo, e, método para reduzir o impacto negativo no ganho de peso diário médio (adwg) de um porco associado com infecção subclínica com lawsonia intracellularis?
AR108792A1 (es) Composiciones que comprenden timolol
EP4356968A3 (en) Long-acting formulations
BR112019002125A2 (pt) composição de comprimidos de alta carga de fármacos para o tratamento do hiv
EA202090287A1 (ru) Составы пролонгированного действия
CL2017001941A1 (es) Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumor
CL2022003689A1 (es) Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4)